{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:44:58Z","timestamp":1791906298064,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd013801","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000}}],"reference-count":84,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013801.pub2","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:29:49Z","timestamp":1760556589000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunoglobulin for myasthenia gravis"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1055-0324","authenticated-orcid":false,"given":"Apostolos","family":"Manolopoulos","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Investigation, Intramural Research Program; National Institute on Aging, NIH; Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muayad","family":"Alzuabi","sequence":"additional","affiliation":[{"name":"Department of Neurology; David Geffen School of Medicine at UCLA; Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Elmashala","sequence":"additional","affiliation":[{"name":"Department of Neurology; Massachusetts General Brigham Hospitals, Harvard Medical School; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cashwell","sequence":"additional","affiliation":[{"name":"Department of Neurology; Cleveland Clinic; Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Mayo Evidence-based Practice Center (EPC); Mayo Clinic; Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-1236","authenticated-orcid":false,"given":"Elie","family":"Naddaf","sequence":"additional","affiliation":[{"name":"Department of Neurology; Mayo Clinic; Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1002\/14651858.CD013801.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","article-title":"Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG","volume":"13","author":"Dewilde","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nature Reviews Disease Primers"},{"issue":"3","key":"10.1002\/14651858.CD013801.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1002\/14651858.CD013801.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/mus.27220","article-title":"Thymoma pathology and myasthenia gravis outcomes","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1002\/14651858.CD013801.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013801.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa","year":"2023","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"8232","key":"10.1002\/14651858.CD013801.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/s0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"issue":"3s","key":"10.1002\/14651858.CD013801.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"7","key":"10.1002\/14651858.CD013801.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinte.1986.00360190143020","article-title":"High-dose intravenous immunoglobulin in the management of myasthenia gravis","volume":"146","author":"Arsura","year":"1986","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0404.1991.tb04912.x","article-title":"Treatment of myasthenia gravis with high-dose intravenous immunoglobulin","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8381","key":"10.1002\/14651858.CD013801.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1749-6632.1987.tb51387.x","article-title":"High-dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange?","volume":"505","author":"Gajdos","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/mus.28289","article-title":"Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: a multicenter, double-blind, placebo-controlled trial","volume":"71","author":"Bril","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","article-title":"Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis","volume":"100","author":"Bril","year":"2023","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"D\u00edez-Porras","year":"2020","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1002\/14651858.CD013801.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s00415-021-10544-3","article-title":"Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis","volume":"268","author":"Wilf-Yarkoni","year":"2021","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013801.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1517\/14740338.2010.484419","article-title":"Safety of intravenous immunoglobulin treatment","volume":"9","author":"Caress","year":"2010","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"120480","DOI":"10.1016\/j.jns.2022.120480","article-title":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","volume":"443","author":"Qi","year":"2022","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD013801.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/CND.0000000000000105","article-title":"Safety and efficacy of subcutaneous immunoglobulin in the treatment of neuromuscular disorders","volume":"17","author":"Salameh","year":"2016","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Schaik","year":"2018","journal-title":"Lancet Neurology"},{"issue":"12","key":"10.1002\/14651858.CD013801.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1007\/s00415-022-11345-y","article-title":"Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study","volume":"269","author":"Barnay","year":"2022","journal-title":"Journal of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD013801.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD013801.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"e0159993","DOI":"10.1371\/journal.pone.0159993","article-title":"Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study","volume":"11","author":"Bourque","year":"2016","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"N4.002","DOI":"10.1212\/WNL.92.15_supplement.N4.002","article-title":"Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study (N4.002)","volume":"92","author":"Dimachkie","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1756285614563056","article-title":"Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction","volume":"8","author":"Hadden","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"Journal of Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nature Reviews Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jocn.2019.08.113","article-title":"Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: a systematic review","volume":"72","author":"Adiao","year":"2020","journal-title":"Journal of Clinical Neuroscience"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013801.pub2-BIB0034|cit34","first-page":"S98","article-title":"Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin","volume":"25","author":"Ness","year":"2019","journal-title":"American Journal of Managed Care"},{"issue":"12","key":"10.1002\/14651858.CD013801.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0036|cit36","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD013801.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013801","article-title":"Immunoglobulin for myasthenia gravis","author":"Alzuabi","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurologic Clinics"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0040|cit40","volume-title":"The Quantitative Myasthenia Gravis (QMG) test: the manual","author":"Barohn","year":"2000"},{"issue":"4","key":"10.1002\/14651858.CD013801.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"10.1002\/14651858.CD013801.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD013801.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD013801.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3109\/09638288.2013.804591","article-title":"Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis","volume":"36","author":"Raggi","year":"2014","journal-title":"Disability and Rehabilitation"},{"issue":"6","key":"10.1002\/14651858.CD013801.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"18","key":"10.1002\/14651858.CD013801.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013801.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.24911","article-title":"Validation of the Besta Neurological Institute rating scale for myasthenia gravis","volume":"53","author":"Antozzi","year":"2016","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1002\/14651858.CD013801.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the Myasthenia Gravis Impairment Index","volume":"9","author":"Barnett","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0051|cit51","unstructured":"EndNote The EndNote Team Clarivate 2013"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0052|cit52","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0053|cit53","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated October 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0054|cit54","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2019"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0055|cit55","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0056|cit56","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0057|cit57","unstructured":"Excel tool to implement RoB 2 https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0058|cit58","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD013801.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0061|cit61","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"issue":"414","key":"10.1002\/14651858.CD013801.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"24","key":"10.1002\/14651858.CD013801.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Statistics in Medicine"},{"issue":"21","key":"10.1002\/14651858.CD013801.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1002\/sim.1262","article-title":"A simple confidence interval for meta-analysis","volume":"21","author":"Sidik","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0065|cit65","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0066|cit66","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0067|cit67","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"Ronager","year":"2001","journal-title":"Artificial Organs"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419864497","article-title":"Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis","volume":"12","author":"Gamez","year":"2019","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0070|cit70","unstructured":"Schuchardt V Kohler W Hund E Scheglmann K Fleischer E Jung K A randomized, controlled trial of high-dose intravenous immunoglobulin versus methylprednisolone in moderate exacerbations of myasthenia gravis: final analysis after early termination Data on file 2004"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0073|cit73","unstructured":"Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis https:\/\/clinicaltrials.gov\/study\/NCT00515450"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2016","journal-title":"Acta Neurologica Belgica"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Therapeutic Apheresis and Dialysis"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0077|cit77","unstructured":"Subcutaneous Immunoglobulin for Myasthenia Gravis (MG_SCIG) https:\/\/clinicaltrials.gov\/study\/NCT04728425"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"7796833","DOI":"10.1155\/2022\/7796833","article-title":"Effects of plasma exchange combined with immunoglobulin therapy on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis: a prospective randomized test","volume":"2022","author":"Peng","year":"2022","journal-title":"Computational And Mathematical Methods In Medicine"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"9786520","DOI":"10.1155\/2023\/9786520","article-title":"Retracted: Effects of plasma exchange combined with immunoglobulin therapy on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis: a prospective randomized test","volume":"2023","author":"Methods In Medicine","year":"2023","journal-title":"Computational and Mathematical Methods in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013801.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1002\/14651858.CD013801.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"11123180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicines"},{"key":"10.1002\/14651858.CD013801.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2024.01.025","article-title":"Assessing the comparative efficacy of plasmapheresis and intravenous immunoglobulin in myasthenia gravis treatment: a systematic review and meta-analysis","volume":"121","author":"Ghimire","year":"2024","journal-title":"Journal of Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD013801.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"103019","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz","year":"2022","journal-title":"Autoimmunity Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:47:39Z","timestamp":1791902859000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013801.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":84,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013801.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}